首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1542516

全球生物製劑合約製造市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Biologics Contract Manufacturing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 141 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球生物製劑合約製造市場需求預計將從 2023 年的 167.7 億美元增至 2032 年近 479.2 億美元，2024-2032 年研究期間複合年成長率為 11.07%。

生物製品合約製造是指將生物製藥產品的生產和製造過程外包給專門的合約製造組織（CMO）。生物製劑是源自活生物體的複雜治療產品，例如蛋白質、抗體、疫苗和基於細胞的療法。它允許製藥公司、生物技術公司和學術機構利用 CMO 的專業知識、能力和基礎設施，以高效且經濟高效的方式大規模生產生物製劑。

市場動態

在其功效和個人化醫療方法的推動下，對生物藥物的需求不斷成長，推動了對高效製造能力的需求。將生物製劑生產外包給專門的合約製造組織 (CMO) 可以為製藥公司提供成本效率和靈活性，使他們能夠專注於核心競爭力並根據需求調整產量。 CMO 滿足製造過程中嚴格的監管標準和品質保證，確保符合法規並維持產品的安全性和有效性。生物加工領域的技術進步進一步提高了生物製品製造的效率和生產力，製藥公司和 CMO 之間的合作夥伴關係推動了創新和簡化流程。生物製藥行業的全球市場擴張以及對生物製劑的日益重視，增強了對可靠和可擴展解決方案的需求。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球生物製品合約製造市場的每個細分市場進行了包容性評估。生物製品合約製造業的成長和趨勢為本研究提供了整體方法。

市場區隔

生物製劑合約製造市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按產品分類

人與生物圈
重組蛋白
其他

按指示

腫瘤學
免疫系統疾病
心血管疾病 (CVD)
血液系統疾病
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲生物製劑合約製造市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。生物製劑合約製造市場的主要參與者包括藥明生物；阿布澤納有限公司；富士軟片 Diosynth 生技公司； BI BioXcellence；龍沙集團股份公司；勃林格殷格翰有限公司；三星生物製劑；艾伯維；康泰倫特；生物依賴性； Eurofins CDMO；賽默飛世爾 (Patheon)。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：生物製品合約製造公司的競爭格局

生物製品合約製造市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Wuxi Biologics

公司概況
公司收入
產品
最新動態

Abzena Ltd.

公司概況
公司收入
產品
最新動態

Fujifilm Diosynth Biotechnologies

公司概況
公司收入
產品
最新動態

BI BioXcellence

公司概況
公司收入
產品
最新動態

Lonza Group AG

公司概況
公司收入
產品
最新動態

Boehringer Ingelheim GmbH

公司概況
公司收入
產品
最新動態

Samsung Biologics

公司概況
公司收入
產品
最新動態

Abbvie

公司概況
公司收入
產品
最新動態

Catalent

公司概況
公司收入
產品
最新動態

Bioreliance

公司概況
公司收入
產品
最新動態

Eurofins CDMO

公司概況
公司收入
產品
最新動態

Thermo Fischer (Patheon)

公司概況
公司收入
產品
最新動態

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112111512

The global demand for Biologics Contract Manufacturing Market is presumed to reach the market size of nearly USD 47.92 Billion by 2032 from USD 16.77 Billion in 2023 with a CAGR of 11.07% under the study period 2024 - 2032.

Biologics contract manufacturing refers to the outsourcing of the production and manufacturing processes of biopharmaceutical products to specialized contract manufacturing organizations (CMOs). Biologics are complex therapeutic products derived from living organisms, such as proteins, antibodies, vaccines, and cell-based therapies. It allows pharmaceutical companies, biotechnology firms, and academic institutions to leverage the expertise, capabilities, and infrastructure of CMOs to efficiently and cost-effectively produce biologics on a large scale.

MARKET DYNAMICS

The increasing demand for biological drugs, driven by their efficacy and personalized medicine approaches, fuels the need for efficient manufacturing capabilities. Outsourcing biologics production to specialized contract manufacturing organizations (CMOs) offers cost efficiency and flexibility for pharmaceutical companies, allowing them to focus on core competencies and adjust production volumes based on demand. The stringent regulatory standards and quality assurance in this manufacturing are met by CMOs, ensuring compliance with regulations and maintaining product safety and efficacy. Technological advancements in bioprocessing further enhance the efficiency and productivity of biologics manufacturing, and collaborative partnerships between pharmaceutical companies and CMOs drive innovation and streamline processes. The global market expansion of the biopharmaceutical industry, along with the growing emphasis on biologics, reinforces the need for reliable and scalable solutions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of biologics contract manufacturing. The growth and trends of biologics contract manufacturing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the biologics contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

MABs
Recombinant Protein
Others

By Indication

Oncology
Immunological Disorders
Cardiovascular Disorders (CVDs)
Hematological Disorders
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Biologics Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the biologics contract manufacturing market include Wuxi Biologics; Abzena Ltd.; FUJIFILM Diosynth Biotechnologies; BI BioXcellence; Lonza Group AG; Boehringer Ingelheim GmbH; Samsung Biologics; Abbvie; Catalent; Bioreliance; Eurofins CDMO; Thermo Fischer (Patheon). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . BIOLOGICS CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY PRODUCT

5.1 Overview by Product
5.2 Historical and Forecast Data
5.3 Analysis by Product
5.4 MABs Historic and Forecast Sales by Regions
5.5 Recombinant Protein Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY INDICATION

6.1 Overview by Indication
6.2 Historical and Forecast Data
6.3 Analysis by Indication
6.4 Oncology Historic and Forecast Sales by Regions
6.5 Immunological Disorders Historic and Forecast Sales by Regions
6.6 Cardiovascular Disorders (CVDs) Historic and Forecast Sales by Regions
6.7 Hematological Disorders Historic and Forecast Sales by Regions
6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE BIOLOGICS CONTRACT MANUFACTURING COMPANIES

8.1. Biologics Contract Manufacturing Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF BIOLOGICS CONTRACT MANUFACTURING INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Wuxi Biologics
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Abzena Ltd.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Fujifilm Diosynth Biotechnologies
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. BI BioXcellence
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Lonza Group AG
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Boehringer Ingelheim GmbH
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Samsung Biologics
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Abbvie
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Catalent
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Bioreliance
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
9.13. Eurofins CDMO
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments
9.14. Thermo Fischer (Patheon)
- 9.14.1. Company Overview
- 9.14.2. Company Revenue
- 9.14.3. Products
- 9.14.4. Recent Developments